Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. liver tissue
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads

Refine by
Date

  • Older

Liver Tissue Articles & Analysis

14 news found

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...

ByInversago Pharma


Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...

ByInversago Pharma


ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

“ASC618, a Second-Generation FVIII Gene Therapy for Hemophilia A, Exhibits Major Transduction and Transgene Expression in the Target Liver Tissues: Results of IND-Enabling Pharmacokinetics Studies in Mice and Non-Human Primates” Tweet this A podium presentation entitled “ASC618, a Second-Generation FVIII Gene Therapy for Hemophilia A, ...

ByASC Therapeutics


Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Hepatic steatosis can progress to nonalcoholic steatohepatitis (NASH) with fibrosis, and NASH-associated liver failure is one of the leading causes of liver transplant in the United States. ...

ByLumos Pharma


Velacur Data Presented at 2021 AASLD The Liver Meeting

Velacur Data Presented at 2021 AASLD The Liver Meeting

When measuring fatty liver disease in obese patients, a greater imaging depth (below subcutaneous fat and the liver capsule) results in a more accurate liver health assessment. ...

BySonic Incytes Medical Corp.


ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021

ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021

Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted ...

ByAspect Biosystems Ltd.


HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy

HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy

Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat. ...

ByHistoSonics


Sonic Incytes Showcases Velacur at ACG 2021

Sonic Incytes Showcases Velacur at ACG 2021

With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...

BySonic Incytes Medical Corp.


Why do you require to have a Liver transplant?

Why do you require to have a Liver transplant?

If anyhow, your liver stops working properly, you may need a liver transplant. Liver Transplant India is generally recommended if you have a last-stage liver disease, which is chronic liver failure. ...

ByLiver Transplant India


HistoSonics Announces Milestone as AMA Issues Unique Category III CPT Code for Histotripsy of Liver

HistoSonics Announces Milestone as AMA Issues Unique Category III CPT Code for Histotripsy of Liver

HistoSonics is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy tissue in the liver without ...

ByHistoSonics


Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row

Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row

“It’s a great honour to be recognized by Rocket Builders for the second year in a row,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Fatty liver disease is an emerging health crisis that affects 1 in 4 people worldwide and, with FDA clearance of VelacurTM, we’re excited to offer health care practitioners a breakthrough, point of care ...

BySonic Incytes Medical Corp.


HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study

HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study

Food and Drug Administration (FDA) to begin a clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tissue and tumors, from outside of the body. The study is a multi-center, open label and single arm trial to evaluate the safety and efficacy in destroying liver ...

ByHistoSonics


Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues

Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues

Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. ...

ByPoietis


New Multi-pronged Injection Needle Receives CE Mark Approval/ 510k Exempt Status (U.S.)

New Multi-pronged Injection Needle Receives CE Mark Approval/ 510k Exempt Status (U.S.)

Conshohocken, PA., September 30, 2003-Rex Medical, L.P., today announced the 510K Exempt Status (U.S.) and CE Mark Approval to market the Quadra-Fuse™ Multi-Pronged Injection Needle designed for the infusion of fluids (chemicals, hypertonic saline, etc.) into soft tissue (liver, other organs, etc.). Quadra-Fuse™ technology is an 18 Gauge ...

ByRex Medical, L.P.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT